2009
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Young A, Oren D, Lowy A, McQuade R, Marcus R, Carson W, Spiller N, Torbeyns A, Sanchez R. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. The British Journal Of Psychiatry 2009, 194: 40-48. PMID: 19118324, DOI: 10.1192/bjp.bp.108.049965.Peer-Reviewed Original ResearchConceptsWeek 12Young Mania Rating Scale (YMRS) total scoreDouble-blind aripiprazoleHaloperidol-treated patientsTolerability of aripiprazoleExtrapyramidal adverse eventsScale total scoreMasked treatmentAdverse eventsClinical improvementAcute maniaAripiprazole monotherapyBipolar maniaMixed episodesEffective therapyEffect therapyAripiprazoleAdditional weeksHaloperidolWeek 3PlaceboPatientsTotal scoreTherapyMania
2007
Intramuscular Aripiprazole in the Control of Agitation
CURRIER G, CITROME L, ZIMBROFF D, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Intramuscular Aripiprazole in the Control of Agitation. Journal Of Psychiatric Practice 2007, 13: 159-169. PMID: 17522559, DOI: 10.1097/01.pra.0000271657.09717.e2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsAripiprazoleArousalBipolar DisorderDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHaloperidolHumansHypnotics and SedativesInjections, IntramuscularLorazepamMaleMiddle AgedMulticenter Studies as TopicPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationQuinolonesRandomized Controlled Trials as TopicSchizophreniaSchizophrenic PsychologyTreatment OutcomeConceptsBipolar I disorderPEC scoresAripiprazole injectionI disordersBaseline agitationSecond injectionNegative Syndrome Scale Excited ComponentBaseline levelsSecondary analysisControl of agitationImportant clinical issueIntramuscular aripiprazoleAnalysis 3Clinical trialsAgitation symptomsMean changeNonspecific sedationPatientsBaseline scoresClinical issuesPlaceboAnalysis 2Analysis 1Study periodSchizophreniaManagement of Acute Agitation in Patients With Bipolar Disorder
Zimbroff D, Marcus R, Manos G, Stock E, McQuade R, Auby P, Oren D. Management of Acute Agitation in Patients With Bipolar Disorder. Journal Of Clinical Psychopharmacology 2007, 27: 171-176. PMID: 17414241, DOI: 10.1097/jcp.0b13e318033bd5e.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAnti-Anxiety AgentsAntipsychotic AgentsAripiprazoleBipolar DisorderDisorders of Excessive SomnolenceDizzinessDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHeadacheHumansInjections, IntramuscularLorazepamMaleNauseaPatient DropoutsPiperazinesPsychomotor AgitationQuinolonesSleep Initiation and Maintenance DisordersTreatment OutcomeVomitingConceptsIM aripiprazoleIM placeboIM lorazepamAcute agitationActive treatmentEfficacy measuresFirst injectionBipolar disorderDouble-blind multicenter studyTreatment of agitationPrimary efficacy measureRisk-benefit profileComponent scoresAripiprazole dosesIntramuscular aripiprazoleOral aripiprazoleMixed episodesMulticenter studySafety profileEfficacy parametersLower incidenceMean changePlaceboAripiprazolePatientsEfficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Tran-Johnson T, Sack D, Marcus R, Auby P, McQuade R, Oren D. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. The Journal Of Clinical Psychiatry 2007, 68: 111-9. PMID: 17284138, DOI: 10.4088/jcp.v68n0115.Peer-Reviewed Original ResearchConceptsPrimary efficacy measureIntramuscular aripiprazoleIM haloperidolIM aripiprazoleAcute agitationAdverse eventsEfficacy measuresTreatment-emergent adverse eventsCommon adverse eventsPlacebo-controlled trialPlacebo-controlled studyControl of agitationSchizo-affective disorderDSM-IV diagnosisNegative Syndrome ScaleHaloperidol groupIntramuscular haloperidolExtrapyramidal symptomsMore patientsInitial dosingSchizophreniform disorderMean changePlaceboSecondary measuresPEC scores
2006
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study*
Andrezina R, Marcus R, Oren D, Manos G, Stock E, Carson W, McQuade R. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study*. Current Medical Research And Opinion 2006, 22: 2209-2219. PMID: 17076982, DOI: 10.1185/030079906x148445.Peer-Reviewed Original ResearchConceptsDouble-blind studyIM haloperidolIM placeboIntramuscular aripiprazoleIM aripiprazoleOral aripiprazoleOral therapyEfficacy measuresIM treatmentPEC scoresExtrapyramidal symptom-related adverse eventsSecondary efficacy measuresPrimary efficacy measureAripiprazole therapyAcute agitationAdverse eventsOral treatmentActive treatmentSafety profileIM injectionMean changeMean improvementPlaceboHaloperidolAripiprazoleIntramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol
Andrezina R, Josiassen R, Marcus R, Oren D, Manos G, Stock E, Carson W, Iwamoto T. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006, 188: 281-292. PMID: 16953381, DOI: 10.1007/s00213-006-0541-x.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAnti-Dyskinesia AgentsAntipsychotic AgentsAripiprazoleBasal Ganglia DiseasesBenzodiazepinesBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationFemaleHaloperidolHumansInjections, IntramuscularMalePiperazinesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaTime FactorsTreatment OutcomeWithholding TreatmentConceptsIM aripiprazoleIM haloperidolAcute agitationIntramuscular aripiprazoleEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPlacebo-controlled studySecondary efficacy measuresPercentage of patientsPlacebo-controlled comparisonPrimary efficacy measureIM placeboIntramuscular haloperidolAdverse eventsMethodsFour hundredThird injectionMean changePlaceboEffective treatmentHaloperidolPatientsAripiprazoleConclusionThese resultsMean number
2005
Circadian Phase Shifting, Alerting, and Antidepressant Effects of Bright Light Treatment
Postolache T, Oren D. Circadian Phase Shifting, Alerting, and Antidepressant Effects of Bright Light Treatment. Clinics In Sports Medicine 2005, 24: 381-413. PMID: 15892931, DOI: 10.1016/j.csm.2004.12.005.Peer-Reviewed Original Research
2004
Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response
Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS. Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. Neuropsychopharmacology 2004, 29: 1166-1171. PMID: 15010697, DOI: 10.1038/sj.npp.1300418.Peer-Reviewed Original ResearchConceptsHamilton depression scale ratingsΑ2-antagonist yohimbineAntidepressant responseClinical Global Impression ratingsBlood pressure changesPercentage of respondersLog-rank testGlobal Impression ratingsMajor depressive disorderMore rapid onsetP subjectsDSM-IV diagnosisSSRI agentsTitrated doseYohimbine doseAntidepressant actionAntidepressant medicationCGI scaleNoradrenergic toneMonoaminergic neurotransmissionΑ2-adrenoceptorsDepressive disorderTreatment periodOutcome measuresSCID interview
2002
An Open Trial of Morning Light Therapy for Treatment of Antepartum Depression
Oren D, Wisner K, Spinelli M, Epperson C, Peindl K, Terman J, Terman M. An Open Trial of Morning Light Therapy for Treatment of Antepartum Depression. American Journal Of Psychiatry 2002, 159: 666-669. PMID: 11925310, DOI: 10.1176/appi.ajp.159.4.666.Peer-Reviewed Original ResearchConceptsWeeks of treatmentMorning light therapyBright light therapyLight therapyAntepartum depressionOpen trialMajor depressionMorning bright light therapyHamilton Depression Rating ScaleSeasonal Affective Disorder VersionDepression Rating ScaleNovel treatment approachesFollow-up questionnairePregnant patientsAntidepressant effectsPregnant womenDepression ratingsTreatment approachesTherapyRating ScaleAdverse effectsDepressionTrialsWeeksPregnancy
2001
Bright Light Therapy for Schizoaffective Disorder
OREN D, CUBELLS J, LITSCH S. Bright Light Therapy for Schizoaffective Disorder. American Journal Of Psychiatry 2001, 158: 2086-a-2087. PMID: 11729035, DOI: 10.1176/appi.ajp.158.12.2086-a.Peer-Reviewed Original Research
2000
No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects
Oren D, Berman R, Anand A, Charney D. No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects. Psychiatry Research 2000, 94: 263-266. PMID: 10889291, DOI: 10.1016/s0165-1781(00)00158-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultDepressive Disorder, MajorFemaleGlucagonHumansMalePhototherapySeasonal Affective DisorderSeasonsTreatment Outcome
1998
Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phase
Coric V, Oren D, Wolkenberg F, Kravitz R. Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phase. Journal Of Neurology Neurosurgery & Psychiatry 1998, 65: 245. PMID: 9703180, PMCID: PMC2170185, DOI: 10.1136/jnnp.65.2.245.Peer-Reviewed Original ResearchConceptsHyperbaric oxygenCarbon monoxide poisoningPatient underwent treatmentAnterograde memory lossCarbon monoxide intoxicationCarbon monoxide exposureAcute confusionNeuropsychiatric functionSubacute phaseSymptom reliefUnderwent treatmentClinical findingsNormobaric oxygenImmediate treatmentBrain injuryTherapeutic windowNeuropsychological testingMatter of debateMemory lossPartial retrogradeTreatmentMonthsPoisoningNormobaricPatients
1996
Dr. Teicher and Colleagues Reply
TEICHER M, GLOD C, OREN D, SCHWARTZ P, BROWN C, ROSENTHAL N. Dr. Teicher and Colleagues Reply. American Journal Of Psychiatry 1996, 153: 1111-1111. PMID: 8678189, DOI: 10.1176/ajp.153.8.1111.Peer-Reviewed Original Research
1995
The phototherapy light visor: more to it than meets the eye
Teicher M, Glod C, Oren D, Schwartz P, Luetke C, Brown C, Rosenthal N. The phototherapy light visor: more to it than meets the eye. American Journal Of Psychiatry 1995, 152: 1197-1202. PMID: 7625470, DOI: 10.1176/ajp.152.8.1197.Peer-Reviewed Original ResearchMeSH KeywordsAdultColorFemaleHumansLightMalePhototherapyPlacebosSeasonal Affective DisorderTreatment OutcomeConceptsAtypical depressive symptomsLight visorDepressive symptomsHamilton Depression Scale scoresHamilton Depression Rating ScaleBaseline depression scoresDepression Rating ScaleDepression Scale scoresFull clinical responseModerate response rateSeasonal affective disorderDim red lightClinical responseTherapeutic responseTreatment periodEffective treatmentDepression scoresPatientsResponse rateScale scoreAffective disordersRating ScaleBright white lightSignificant differencesSymptoms
1994
A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder
Oren D, Teicher M, Schwartz P, Glod C, Turner E, Ito Y, Sedway J, Rosenthal N, Wehr T. A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder. Journal Of Affective Disorders 1994, 32: 197-200. PMID: 7852661, DOI: 10.1016/0165-0327(94)90018-3.Peer-Reviewed Original ResearchConceptsSeasonal affective disorderWinter seasonal affective disorderAffective disordersEffective short-term treatmentWeekly outpatient visitsShort-term treatmentSIGH-SAD scoresPlacebo washoutAntidepressant efficacyOutpatient visitsWashout periodEffective treatmentSame scheduleVitamin B12SAD patientsSignificant differencesTreatmentPatientsWeeksDisordersCyanocobalaminRandom assignmentPlaceboTrialsVisits